Handbook of therapeutic antibodies
Handbook of therapeutic antibodies
复制标题
治疗性抗体手册
DOI：
10.1002/9783527619740
复制
发表时间：
2007
期刊：
影响因子：
--
通讯作者：
J. Reichert
中科院分区：
文献类型：
--
作者：
Stef An D bel;J. Reichert
第一卷：第0部分：引言治疗性抗体-从过去到未来第一部分：抗体分子的选择和成形选择策略I：单克隆抗体选择策略II：抗体噬菌体展示选择策略III：转基因小鼠抗体工程的生物信息学工具分子工程I：人源化分子工程II：亲和力成熟分子工程III：Fc工程第二部分：进入药物生产和下游加工的途径药物制剂和临床应用抗体治疗的免疫原性法规考虑知识产权问题第二卷：新兴发展第三部分：超越IGG：修饰抗体免疫闪烁成像和放射免疫治疗双特异性抗体免疫毒素/靶向RNA酶第四部分：新兴概念选择和工程自动化新兴技术抗体选择新兴替代生产系统非抗体支架新兴治疗概念I：ADEPT新兴治疗概念II：纳米技术新兴治疗概念III：细胞结合抗体新兴治疗概念IV：抗独特型抗体第五部分：正在进行的临床研究：I/II/III期抗体：癌症治疗I/II/III期抗体：靶向TNF第三卷：获批治疗药物阿达木单抗（修美乐）阿仑单抗（美罗华）贝伐珠单抗（安维汀）西妥昔单抗（爱必妥）依法珠单抗（Raptiva）法诺索单抗/锝99 m（Neutrospec）吉妥珠单抗（Mylotarg）英夫利西单抗（类克）莫罗单抗（Orthoclone）那他珠单抗（Tysabri）奥马珠单抗（Xolair）帕利珠单抗（Synagis）利妥昔单抗（Rituxan）曲妥珠单抗（赫赛汀）概述：阿昔单抗、Arcitumomab、巴利昔单抗、Caproumab、Cotara、Daclizumab、依地莫单抗、替伊莫单抗、Igovomab、诺非莫单抗、Satumomab、Sulesomab、托西莫单抗和Votumumab
Volume I: Technologies Foreword A Greeting from the Editor PART 0: INTRODUCTION Therapeutic Antibodies - From Past to Future PART I: SELECTING AND SHAPING THE ANTIBODY MOLECULE Selection strategies I: Monoclonal Antibodies Selection strategies II: Antibody Phage Display Selection strategies III: Transgenic Mice Bioinformatic Tools for Antibody Engineering Molecular Engineering I: Humanization Molecular Engineering II: Affinity Maturation Molecular Engineering III: Fc Engineering PART II: THE WAY INTO THE CLINIC Production and Downstream Processing Pharmaceutical Formulation and Clinical Application Immunogenicity of Antibody Therapeutics Regulatory Considerations Intellectual Property Issues Volume II: Emerging Developments PART III: BEYOND IGG: MODIFIED ANTIBODIES Immunoscintigraphy and Radioimmunotherapy Bispecific Antibodies Immunotoxins / Targeted RNases PART IV: EMERGING CONCEPTS Automation of Selection and Engineering Emerging Technologies for Antibody Selection Emerging Alternative Production Systems Non-Antibody Scaffolds Emerging Therapeutic Concepts I: ADEPT Emerging Therapeutic Concepts II: Nanotechnology Emerging Therapeutic Concepts III:Cell-bound antibodies Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies PART V: ONGOING CLINICAL STUDIES: Antibodies in Phase I/II/III: Cancer Therapy Antibodies in Phase I/II/III: Targeting TNF VOLUME III: APPROVED THERAPEUTICS Adalimumab (Humira) Alemtuzumab (Mabcampath) Bevacizumab (Avastin) Cetuximab (Erbitux) Efalizumab (Raptiva) Fanolesomab/Technetium99m (Neutrospec) Gemtuzumab Ozogamicin (Mylotarg) Infliximab (Remicade) Muromonab (Orthoclone) Natalizumab (Tysabri) Omalizumab (Xolair) Palivizumab (Synagis) Rituximab (Rituxan) Trastuzumab (Herceptin) Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Ibritumomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab